Albumin carrier therapy with methotrexate (MTX-HSA)

A well-tolerated therapy component for advanced tumour diseases with antiproliferative, anti-inflammatory and immunomodulatory effects.

Within evidence-based oncology, the survival time of patients with metastatic cancer has not been significantly extended in recent decades, despite sometimes aggressive treatment regimens. In addition, these therapies have usually severely restricted the patients’ quality of life. MTX-HSA now offers a therapy with few side effects which, combined with other cancer therapies, can bring considerable added value.